SARS-CoV-2-specific immune responses after COVID-19 vaccination in end-stage renal disease patients and kidney transplant recipients

Completed

• Conditions: ESRD; quantiferon; SARS-CoV-2; humoral immunity; Healthy volunteers, patients with end-stage renal disease on hemodialysis, peritoneal dialysis, or receiving kidney transplantation.; kidney transplant

• Registration Number: TCTR20210226002
• Lead Sponsor: ational Research Council of Thailand (NRCT).

Brief Summary

Our findings revealed weak HMI but comparable CMI responses in fully vaccinated KT recipients receiving inactivated SARS-CoV-2 vaccination compared to immunocompetent individuals.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-26
• Study Completion: 2021-07-18
• Results First Posted: 2021-10-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Healthy subjects, ESRD patients, or kidney transplant recipients who are willing to participate in the project.

Exclusion Criteria

Those who received the COVID-19 vaccine prior to

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SARS-CoV-2-specific immunity at day 28 and 56 Neutralizing antibody test, Quantiferon SARS-CoV-2

Secondary Outcome Measures

Name	Time	Method
COVID-19 within 6 months after vaccination SARS-CoV-2 RT-PCR